Cite
HARVARD Citation
Donovan, J. et al. (2017). A Novel NF‐κB Inhibitor, Edasalonexent (CAT‐1004), in Development as a Disease‐Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects. Journal of clinical pharmacology. pp. 627-639. [Online].